1. Home
  2. MSD vs NERV Comparison

MSD vs NERV Comparison

Compare MSD & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Morgan Stanley Emerging Markets Debt Fund Inc.

MSD

Morgan Stanley Emerging Markets Debt Fund Inc.

HOLD

Current Price

$6.91

Market Cap

146.9M

Sector

Finance

ML Signal

HOLD

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$3.50

Market Cap

166.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MSD
NERV
Founded
1993
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
146.9M
166.4M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
MSD
NERV
Price
$6.91
$3.50
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.50
AVG Volume (30 Days)
56.4K
131.7K
Earning Date
01-01-0001
05-01-2026
Dividend Yield
11.26%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$41,175,600.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.91
$2.06
52 Week High
$7.94
$12.46

Technical Indicators

Market Signals
Indicator
MSD
NERV
Relative Strength Index (RSI) 37.46 40.25
Support Level $6.91 N/A
Resistance Level $7.44 $4.73
Average True Range (ATR) 0.07 0.27
MACD -0.01 -0.05
Stochastic Oscillator 16.40 25.55

Price Performance

Historical Comparison
MSD
NERV

About MSD Morgan Stanley Emerging Markets Debt Fund Inc.

Morgan Stanley Emerg Mkts Debt Fd Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to produce high current income and as a secondary objective to seek capital appreciation, through investments mainly in debt securities of government and government-related issuers located in emerging countries, of entities organized to restructure the outstanding debt of such issuers and debt securities of corporate issuers in or organized under the laws of emerging countries.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Share on Social Networks: